Please wait while the transcript is being prepared...
0:00
So this is the second lecture on current dengue
vaccine development,
and in the first lecture
we described the vaccine
under current development,
and exactly where they are
in the development process.
Now we're going to talk about
how are we going to implement
these vaccines, how we're going
to use them, and what problems
can we expect, and how
can they be solved.
So problems to be solved.
0:27
And these are the topics that
we'll discuss in this lecture.
First, when will dengue
vaccines come online?
Second, what are the global
dengue vaccine needs?
Third, what are the
complexities that
we're going to have to confront
with, as we've seen, a Sanofi,
which is just a partially
efficacious vaccine,
it's not a 100% against
all four viruses.
How are we going to immunize the
two distinctly different groups
who are at risk to dengue disease?
And how can we stop or
reduce dengue transmission?
Fourth, how can dengue
vaccines be improved?
And here we need to understand
the complication of antibody
dependent enhancement,
abbreviated ADE,
and to understand better
how protection is induced
against dengue
infection and disease,
both in the natural setting,
and also from vaccines.
And here we're going to need
greater attention to and support
from basic research, and finally,
the use of a human challenge model
in which human beings
who have been vaccinated
will actually be challenged
by a live, somewhat modified
dengue virus.
